<p>Bioventus, Inc. 最近召开了第三季度财报电话会议，整体情绪积极。公司报告了显著的有机增长、盈利能力改善以及在新市场的战略进展。此外，Bioventus 展现了有效的现金和债务管理。然而，由于之前的剥离和外汇损失，公司面临了一些挑战。</p>
<h2>有机收入增长</h2>
<p>Bioventus 报告第三季度有机收入增长了令人印象深刻的 8%。这一增长在所有业务部门均有体现，达到了中低个位数到低双位数的增长。公司在这些领域的市场表现优于同行，突显了其强大的竞争地位和有效的增长策略。</p>
<h2>调整后 EBITDA 和利润率扩张</h2>
<p>公司调整后的 EBITDA 增长了 13%，利润率扩张超过 200 个基点。这一改善凸显了 Bioventus 的运营效率以及通过战略举措提升盈利能力的能力。</p>
<h2>自由现金流加速</h2>
<p>Bioventus 的自由现金流显著加速，第三季度的运营现金几乎是去年同期的三倍。公司实现了超过 100% 的现金转化率，表明其财务健康状况良好，现金管理实践有效。</p>
<h2>外周神经刺激和 PRP 开发</h2>
<p>StimTrial 和 TalisMann 的推出在获得 FDA 批准后获得了积极反馈，新 PRP 系统 Excel 也同样受到好评。Bioventus 预计这些创新将在 2026 年之前为盈利增长贡献 200 个基点，突显了公司在推进产品供应方面的承诺。</p>
<h2>减债</h2>
<p>在本季度，Bioventus 成功减少了 1900 万美元的债务，并计划在年底前将净杠杆降低到 2.5 倍以下。这一减债的重点反映了公司加强资产负债表和提升财务稳定性的战略方法。</p>
<h2>剥离和外汇影响</h2>
<p>尽管增长积极，Bioventus 的收入与去年相比保持不变，原因是其先进康复业务的剥离。此外，外汇汇率的不利影响导致了 50 万美元的意外损失，给公司的财务表现带来了挑战。</p>
<h2>前瞻性指导</h2>
<p>Bioventus 重申了其全年指导，强调其强劲的第三季度表现。公司报告第三季度收入为 1.39 亿美元，反映出 8% 的有机增长。调整后的 EBITDA 增长了 13%，达到 2700 万美元，利润率扩张超过 200 个基点。调整后的每股收益激增 200%，达到 0.15 美元。Bioventus 仍然有望实现全年调整后 EBITDA 利润率扩张 100 个基点，并计划调整后的每股收益在 0.64 到 0.68 美元之间。公司还强调了在疼痛治疗业务中的战略增长机会，预计到 2026 年将为盈利增长带来 200 个基点的提升。</p>
<p>总之，Bioventus 的第三季度财报电话会议反映了积极的情绪，得益于显著的有机增长、盈利能力改善和战略进展。尽管面临剥离和外汇损失的挑战，公司展现了有效的现金和债务管理。展望未来，Bioventus 对其增长前景和财务表现保持乐观，专注于核心业务领域的战略机会。</p>

<p>Bioventus, Inc. 报告了强劲的第三季度业绩， organic revenue 增长了 8%，调整后的 EBITDA 上升了 13%，自由现金流显著加速。该公司成功减少了 1900 万美元的债务，并计划将净杠杆降低至 2.5 倍以下。尽管面临剥离和外汇损失的挑战，Bioventus 仍然保持乐观，重申其全年指引，预计调整后的每股收益在 0.64 美元至 0.68 美元之间，并专注于疼痛治疗的战略增长机会</p>

<p>Bioventus, Inc. recently held its third-quarter earnings call, which was marked by a positive sentiment overall. The company reported significant organic growth, improvements in profitability, and strategic advancements in new markets. Additionally, Bioventus demonstrated effective cash and debt management. However, the company faced challenges due to prior divestitures and foreign exchange losses.</p>
<div class="lb-trans"><p>Bioventus, Inc. 最近召开了第三季度财报电话会议，整体情绪积极。公司报告了显著的有机增长、盈利能力改善以及在新市场的战略进展。此外，Bioventus 展现了有效的现金和债务管理。然而，由于之前的剥离和外汇损失，公司面临了一些挑战。</p>
</div><h2>Organic Revenue Growth</h2>
<div class="lb-trans"><h2>有机收入增长</h2>
</div><p>Bioventus reported an impressive 8% increase in third-quarter revenue on an organic basis. This growth was observed across all business segments, achieving mid-single-digit to low double-digit increases. The company’s ability to outperform the market in these segments highlights its strong competitive position and effective growth strategies.</p>
<div class="lb-trans"><p>Bioventus 报告第三季度有机收入增长了令人印象深刻的 8%。这一增长在所有业务部门均有体现，达到了中低个位数到低双位数的增长。公司在这些领域的市场表现优于同行，突显了其强大的竞争地位和有效的增长策略。</p>
</div><h2>Adjusted EBITDA and Margin Expansion</h2>
<div class="lb-trans"><h2>调整后 EBITDA 和利润率扩张</h2>
</div><p>The company saw a 13% rise in adjusted EBITDA, accompanied by a margin expansion of over 200 basis points. This improvement underscores Bioventus’s operational efficiencies and its ability to enhance profitability through strategic initiatives.</p>
<div class="lb-trans"><p>公司调整后的 EBITDA 增长了 13%，利润率扩张超过 200 个基点。这一改善凸显了 Bioventus 的运营效率以及通过战略举措提升盈利能力的能力。</p>
</div><h2>Free Cash Flow Acceleration</h2>
<div class="lb-trans"><h2>自由现金流加速</h2>
</div><p>Bioventus experienced a significant acceleration in free cash flow, with cash from operations nearly tripling in the third quarter compared to the previous year. The company achieved a cash conversion ratio of over 100%, indicating strong financial health and effective cash management practices.</p>
<div class="lb-trans"><p>Bioventus 的自由现金流显著加速，第三季度的运营现金几乎是去年同期的三倍。公司实现了超过 100% 的现金转化率，表明其财务健康状况良好，现金管理实践有效。</p>
</div><h2>Peripheral Nerve Stimulation and PRP Development</h2>
<div class="lb-trans"><h2>外周神经刺激和 PRP 开发</h2>
</div><p>The launch of StimTrial and TalisMann, following FDA clearance, received positive feedback, as did the new PRP system, Excel. Bioventus anticipates these innovations will contribute to a 200 basis point increase in profitable growth by 2026, highlighting the company’s commitment to advancing its product offerings.</p>
<div class="lb-trans"><p>StimTrial 和 TalisMann 的推出在获得 FDA 批准后获得了积极反馈，新 PRP 系统 Excel 也同样受到好评。Bioventus 预计这些创新将在 2026 年之前为盈利增长贡献 200 个基点，突显了公司在推进产品供应方面的承诺。</p>
</div><h2>Debt Reduction</h2>
<div class="lb-trans"><h2>减债</h2>
</div><p>During the quarter, Bioventus successfully reduced its debt by $19 million and plans to decrease net leverage below 2.5x by the end of the year. This focus on debt reduction reflects the company’s strategic approach to strengthening its balance sheet and enhancing financial stability.</p>
<div class="lb-trans"><p>在本季度，Bioventus 成功减少了 1900 万美元的债务，并计划在年底前将净杠杆降低到 2.5 倍以下。这一减债的重点反映了公司加强资产负债表和提升财务稳定性的战略方法。</p>
</div><h2>Impact of Divestiture and Foreign Exchange</h2>
<div class="lb-trans"><h2>剥离和外汇影响</h2>
</div><p>Despite the positive growth, Bioventus’s revenue remained unchanged compared to the prior year due to the divestiture of its advanced rehabilitation business. Additionally, foreign currency exchange rates had an unfavorable impact, resulting in a $0.5 million unplanned loss, posing a challenge to the company’s financial performance.</p>
<div class="lb-trans"><p>尽管增长积极，Bioventus 的收入与去年相比保持不变，原因是其先进康复业务的剥离。此外，外汇汇率的不利影响导致了 50 万美元的意外损失，给公司的财务表现带来了挑战。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Bioventus reiterated its full-year guidance, emphasizing its robust third-quarter performance. The company reported a third-quarter revenue of $139 million, reflecting 8% organic growth. Adjusted EBITDA rose by 13% to $27 million, with a margin expansion of over 200 basis points. Adjusted earnings per share surged by 200% to $0.15. Bioventus remains on track to achieve a full-year adjusted EBITDA margin expansion of 100 basis points and aims for adjusted EPS between $0.64 to $0.68. The company also highlighted strategic growth opportunities in its pain treatments business, projecting a 200 basis point boost in profitable growth for 2026.</p>
<div class="lb-trans"><p>Bioventus 重申了其全年指导，强调其强劲的第三季度表现。公司报告第三季度收入为 1.39 亿美元，反映出 8% 的有机增长。调整后的 EBITDA 增长了 13%，达到 2700 万美元，利润率扩张超过 200 个基点。调整后的每股收益激增 200%，达到 0.15 美元。Bioventus 仍然有望实现全年调整后 EBITDA 利润率扩张 100 个基点，并计划调整后的每股收益在 0.64 到 0.68 美元之间。公司还强调了在疼痛治疗业务中的战略增长机会，预计到 2026 年将为盈利增长带来 200 个基点的提升。</p>
</div><p>In summary, Bioventus’s third-quarter earnings call reflected a positive sentiment, driven by significant organic growth, profitability improvements, and strategic advancements. Despite challenges from divestitures and foreign exchange losses, the company demonstrated effective cash and debt management. Looking forward, Bioventus remains optimistic about its growth prospects and financial performance, with a focus on strategic opportunities in its core business segments.</p>
<div class="lb-trans"><p>总之，Bioventus 的第三季度财报电话会议反映了积极的情绪，得益于显著的有机增长、盈利能力改善和战略进展。尽管面临剥离和外汇损失的挑战，公司展现了有效的现金和债务管理。展望未来，Bioventus 对其增长前景和财务表现保持乐观，专注于核心业务领域的战略机会。</p>
</div>

Bioventus, Inc. 报告第三季度盈利强劲增长